 LA JOLLA, Calif., March 9, 2021 PRNewswire -- Regulus Therapeutics Inc. Nasdaq: RGLS, a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs the Company or Regulus, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update. 